BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-14.46%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$1.39B
AUM Growth
+$1.39B
(-15%)
Cap. Flow
+$1.43M
Cap. Flow
% of AUM
0.1%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
Lineage Cell Therapeutics
LCTX
|
$1.43M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 55.42% |
| 2 | Consumer Staples | 26.82% |
| 3 | Industrials | 7.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
STAAR Surgical
STAA
$1.36B
| $687M | 49.5% | 8,592,007 | – | – |
|
2
Monster Beverage
MNST
$60.9B
| $372M | 26.82% | 4,656,488 | – | – |
|
3
iShares Russell 2000 ETF
IWM
$67B
| $142M | 10.21% | 690,000 | – | – |
|
4
Axon Enterprise
AXON
$58.7B
| $105M | 7.55% | 760,062 | – | – |
|
|
5
Lineage Cell Therapeutics
LCTX
$267M
| $53.8M | 3.88% | 34,935,485 +930,106 | +3% | +$1.43M |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $25.9M | 1.86% | 17,349,945 | – | – |
|
7
Serina Therapeutics
SER
$54.5M
| $2.56M | 0.18% | 2,997,156 | – | – |
|